[ OptiNose raises $37M in Series D ]

OptiNose has raised $37 million in Series D funding.

Founded in 2000, Optinose develops and commercializes prescription medications, vaccines, biologics and over-the-counter medications for nasal inflammatory diseases.

OptiNose will use the additional capital to fund commercial readiness for the launch of its lead product candidate, OPN-375, in the United States. OPN-375, is an EDS with fluticasone propionate and is being developed for treatment of nasal diseases characterized by chronic inflammation deep in the nose, such as nasal polyposis and chronic sinusitis.

Funding  Series D
Founded  2000
Country  Norway
City  Oslo
Founder / CEO  Peter K. Miller
Deal Size  $37M
Investors  Entrepreneurs Fund
 Avista Capital Partners
 Fidelity Management and Research Company
Previous Investors  WFD Ventures
 Avista Capital Partners
 Entrepreneurs Fund